I am a scientist working on 3rd gen nanopore sequencing technology. I work on mostly the upstream biochemistry, but as of late I have been dealing with novel technologies, instrumentation, and IP as well. Right now I am working on assembling metrics on both 2nd gen and 3rd gen sequencing to see that task ahead. With these emerging technologies it is amazing to see how much out there is just smoke and mirrors. This site is great for looking behind the curtain. Hopefully more "truthiness" and sharing that this site fosters will help this industry mature to a point where true advancements can be made for the people not the pockets.
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...